StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: Goldman Sachs Downgrades Biogen (BIIB) to Buy
April 25, 2018 12:56 AM
(Updated - April 25, 2018 4:39 AM EDT)
(updated to add analyst comment)Goldman Sachs downgraded Biogen (NASDAQ: BIIB) from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Hot Downgrades
Next Articles
Biogen (BIIB) PT Lowered to $272 at Cantor Fitzgerald
April 26, 2018 1:49 AM
Biogen (BIIB) PT Lowered to $311 at RBC Capital
April 25, 2018 7:43 AM
Biogen (BIIB) PT Raised to $369 at Morgan Stanley
April 25, 2018 7:24 AM
Biogen (BIIB) PT Lowered to $375 at Oppenheimer
April 25, 2018 7:15 AM
Biogen (BIIB) PT Lowered to $325 at Leerink Partners
April 25, 2018 6:37 AM
Biogen (BIIB) PT Lowered to $385 at Guggenheim
April 25, 2018 2:03 AM
UPDATE: Baird Upgrades Biogen (BIIB) to Outperform
April 25, 2018 1:08 AM
Biogen (BIIB) PT Lowered to $353 at Piper Jaffray
April 24, 2018 1:30 PM
Biogen (BIIB) Tops Q1 EPS by 13c, Miss on Revenues
April 24, 2018 7:00 AM
